Table 1.
Gene | Function to Inflammasome | Mechanism | Deficiency or Variant | Variant Impact to Disease | Disease or Model | Reference |
---|---|---|---|---|---|---|
IRGM | Inhibit NLRP3 inflammasome assambly | Interact with NLRP3 and Promote NLRP3 autophagic degradation | Deficiency | Exacerbate colitis | DSS-colitis in mouse | [49] |
RIPK1 | Inhibit NLRP3 inflammasome activation upon LPS stimulation | Not clear | Deficiency | Primary immunodeficiency and/or colitis | Human colitis | [51] |
BTK | Inhibit NLRP3 inflammasome activation | Inhibit PP2A mediated NLRP3 dephosphorylation | Deficiency | Exacerbate colitis | DSS-colitis, TNBS-colitis in mouse | [53] |
PTPN2 | Inhibit NLRP3 inflammasome activation | Inhibit JNK and ASC phosphorylation | Deficiency in myeloid cell | Exacerbate colitis | DSS-colitis in mouse | [54] |
Jmjd3 | Enhance NLRP3 inflammasome activation | Prevent H3K27me3 mediated inhibition of Nrf2 | Inhibition or Knock-down | Ameliorate colitis | DSS-colitis | [55] |
miR-223 | Inhibit NLRP3 inflammasome activation | Bind to NLRP3 3’ untranslated region to inhibit inflammasome assembly | Deficiency | Exacerbate colitis | DSS-colitis in mouse | [56] |
NLRP3 mutation | Enhance NLRP3 inflammasome activation | Enhance deubiquitination of NLRP3 via binding with BRCC3 and JOSD2 | R779C | Exacerbate colitis | DSS-colitis in mouse | [61] |
COMMD10 | Inhibit NLRP3 inflammasome activation | Inhibit transcription of inflammasome components | Deficiency in monocytes | Exacerbate colitis | DSS-colitis in mouse | [62] |
CARD8 | Inhibit NLRP3 inflammasome assembly | Interact with NLRP3 and inhibit NLRP3 oligomerization | V44I | Exacerbate colitis | Crohn’s disease | [63] |
IL-10R | Inhibit NLRP3 inflammasome activation | Inhibit expression of NLRP3 and IL-1β | Deficiency | Spontaneous colitis in mouse and infant-onset IBD in human | Mouse spontaneous colitis and human IBD | [64] |
NADPH oxidase | Inhibit NLRP3 inflammasome activation | Induce autophagy | Deficiency | Exacerbate colitis | TNBS-colitis in mouse | [65] |
CD1d1 | Reduce transcription of NLRP3 inflammasome components | Reduce peroxiredoxin 1/ATK/STAT1 mediated NF-kB signaling | Deficiency in macrophage | Ameliorate colitis | DSS-colitis in mouse | [44] |
PTPN22 | Enhance NLRP3 inflammasome activation | Induce NLRP3 dephosphorylation at Tyr861 | Deficiency | Exacerbate colitis | DSS-colitis in mouse | [45] |
V619W | Ameliorate colitis | DSS-colitis in mouse | [45] |
Abbreviations: IRGM: Immunity-related GTPase family M; RIPK1: Receptor interacting protein kinase 1; BTK: Bruton’s tyrosine kinase; XLA: X-linked agammaglobulinemia; PTPN2, 22: protein tyrosine phosphatase non-receptor type 2, 22; Jmjd3: Jumonji domain-containing 3; VEOIBD: Very-Early-Onset inflammatory bowel disease; COMMD10: COMM domain containing 10; CARD8: caspase recruitment domain family member 8; CGD: chronic granulomatous disease; PP2A: serine/threonine protein phosphatase 2A; DSS: Dextran Sodium Sulfate; TNBS: 2,4,6-trinitrobenzene sulfonic acid; PPARγ: peroxisome proliferator-activated receptor γ; SO2: sulfur dioxide; and CysA: cyclosporin A.